Last month, Bristol Myers Squibb (NYSE: BMY) shared that its locally advanced or metastatic non-small cell lung cancer (NSCLC) drug candidate repotrectinib was accepted for priority review by the U.S. Food and Drug Administration (FDA).

Since the FDA expects to reach a decision on repotrectinib by late November of this year, now would be an appropriate time to determine its sales potential. To do so, let's dig into its phase 1/2 clinical trial results and the non-small cell lung cancer drug market.

Lung cancer is the leading cause of cancer death in the United States. It's estimated that 127,000 patients succumb to the disease each year. The vast majority (up to 84%) of these cancer cases are the type known as non-small cell lung cancer (NSCLC). The symptoms of lung cancer can include chest pain, a persistent cough, fatigue, and unintentional weight loss.

Continue reading

Source Fool.com